



Département de psychiatrie
Centre de neurosciences psychiatriques
Site de Cery
CH-1008 Prilly - Lausanne

Le Centre de Neurosciences Psychiatriques et le Service d'alcoologie

ANNOUNCEMENT

Friday, September 13, 2013, 9:30am

“Gabapentin as a Novel Treatment for Alcohol and Cannabis Dependence”

Barbara J Mason PhD

Pearson Family Professor, Committee on the Neurobiology of Addictive Disorders
Director, Laboratory of Clinical Psychopharmacology
Co-Director, Pearson Center for Alcoholism and Addiction Research
The Scripps Research Institute

Invited by Prof. Jean-Bernard Daeppen and Dr. Benjamin Boutrel
(Jean-Bernard.Daeppen@chuv.ch)
(Benjamin.Boutrel@chuv.ch)

**Salle Andros (PMU 08)
Rue du Bugnon 44
1011 Lausanne**

Based on positive findings in pre-clinical and human laboratory models of alcohol dependence, a series of randomized controlled trials were conducted in outpatients with cannabis dependence or alcohol dependence. For both substance use disorders, gabapentin was associated with significant reductions in substance use, craving, and substance-related disturbances in sleep and mood, with a favorable safety profile.

References :

- Mason BJ, Crean R, Goodell V, Light JM, Quello S, Shadan F, Buffkins K, Kyle M, Adusumalli M, Begovic A, Rao S (2012) A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults. *Neuropsychopharmacology*, 37(7): 1689-1698
- Mason BJ, Higley AE (2013) A translational approach to novel medication development for protracted abstinence. *Curr Top Behav Neurosci*, 13:647-70
- Koob GF, Kenneth Lloyd G, Mason BJ. (2009) Development of pharmacotherapies for drug addiction: a Rosetta stone approach. *Nat Rev Drug Discov*. 8(6): 500-515